Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 26% ± 9% | |
glutamatergic neuron | 3 studies | 32% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 25% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 245.94 | 1444 / 1445 | 97% | 6.78 | 178 / 183 |
breast | 100% | 328.27 | 459 / 459 | 96% | 7.76 | 1074 / 1118 |
uterus | 100% | 367.67 | 170 / 170 | 94% | 7.92 | 432 / 459 |
stomach | 100% | 188.33 | 359 / 359 | 93% | 5.54 | 266 / 286 |
intestine | 100% | 270.35 | 966 / 966 | 93% | 5.28 | 489 / 527 |
lung | 99% | 220.56 | 574 / 578 | 93% | 6.00 | 1074 / 1155 |
bladder | 100% | 275.29 | 21 / 21 | 92% | 6.57 | 464 / 504 |
skin | 100% | 363.00 | 1806 / 1809 | 90% | 6.07 | 427 / 472 |
ovary | 100% | 358.60 | 180 / 180 | 86% | 4.69 | 371 / 430 |
pancreas | 96% | 113.84 | 314 / 328 | 70% | 2.69 | 124 / 178 |
brain | 93% | 169.34 | 2462 / 2642 | 72% | 2.92 | 509 / 705 |
thymus | 100% | 282.08 | 653 / 653 | 54% | 2.05 | 324 / 605 |
liver | 97% | 178.00 | 219 / 226 | 53% | 2.65 | 216 / 406 |
prostate | 100% | 279.12 | 245 / 245 | 47% | 1.32 | 238 / 502 |
kidney | 97% | 146.67 | 86 / 89 | 33% | 0.95 | 297 / 901 |
adrenal gland | 98% | 186.73 | 252 / 258 | 11% | 0.36 | 25 / 230 |
spleen | 100% | 325.15 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.88 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.83 | 1 / 1 |
blood vessel | 100% | 219.92 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 279.83 | 1202 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 7.21 | 27 / 29 |
heart | 89% | 111.79 | 769 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 85% | 380.52 | 792 / 929 | 0% | 0 | 0 / 0 |
muscle | 83% | 85.09 | 668 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 0.59 | 20 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045859 | Biological process | regulation of protein kinase activity |
GO_0036297 | Biological process | interstrand cross-link repair |
GO_0000278 | Biological process | mitotic cell cycle |
GO_0007059 | Biological process | chromosome segregation |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_0000776 | Cellular component | kinetochore |
GO_0030496 | Cellular component | midbody |
GO_0051233 | Cellular component | spindle midzone |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019901 | Molecular function | protein kinase binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FIRRM |
Protein name | FIGNL1-interacting regulator of recombination and mitosis (FIDGETIN-like-1 interacting protein) (FLIP) (POLO1-associating protein) Chromosome 1 open reading frame 112 |
Synonyms | APOLO1 C1orf112 |
Description | FUNCTION: Regulates PLK1 kinase activity at kinetochores and promotes faithful chromosome segregation in prometaphase by bridging kinase and phosphatase activities . Phosphorylation of FIRRM by PLK1 negatively regulates its interaction with the phosphatase, PPP1CC, thus creating a negative feedback loop for maintaining proper PLK1 kinase activity during mitosis . In complex with FIGL1 may regulate homologous recombination . . |
Accessions | ENST00000413811.3 [Q9NSG2-3] ENST00000459772.5 ENST00000481744.5 A0A1B0GV14 ENST00000359326.9 [Q9NSG2-1] A0A1B0GUP7 ENST00000472795.5 Q9NSG2 ENST00000496973.5 ENST00000466580.6 A0A1B0GTJ9 ENST00000286031.10 [Q9NSG2-1] |